Buprenorphine Combination Tablet Feasibility - 1

National Institutes of Health (NIH)

Status and phase: Completed; Phase 2

Conditions: Opioid-Related Disorders

Treatments: Drug: Buprenorphine/naloxone

Study type: Interventional

Funder types: NIH

Identifiers

NCT00000298

P50-09260-1

NIDA-09260-1

Details and patient eligibility

About

The purpose of this study is to determine target dose range of buprenorphine/naloxone combination tablet that provides therapeutic response in opiate addicts with low to moderate dependence, and to identify appropriate initial induction dose in opiate addicts with low to moderate dependence."

Sex: All

Ages: 21 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Males/Females ages 21-50, opiate dependence according to DSM-IV criteria, self-reported use within the last 30 days, agreeable to conditions of study and signed informed consent

Exclusion criteria

Psychiatric disorder that requires medication therapy, history of seizures, pregnant and/or nursing women, dependence on etoh or benzodiazepines or other sedative-hypnotics, acute hepatitis, other medical conditions that deem participation to be unsafe.